Drug Profile
NOV 9
Alternative Names: LKA-651; NOV-9Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Alcon; MorphoSys
- Developer Novartis
- Class Antibodies; Eye disorder therapies
- Mechanism of Action Erythropoietin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic macular oedema
- No development reported Retinal oedema
Most Recent Events
- 28 Sep 2022 NOV 9 is still in phase II trial for Diabetic macular oedema in Germany, Puerto Rico, Spain, Turkey, USA (Intravitreous) (NCT03927690)
- 31 Aug 2022 Novartis completes a phase II trial for Diabetic macular oedema in Germany, Puerto Rico, Spain, Turkey and USA (Intravitreous) (NCT03927690)
- 06 May 2020 No development reported - Phase-I for Retinal oedema in Puerto Rico, USA (Intravitreous)